Tenax Therapeutics, Inc. (NASDAQ:TENX – Free Report) – Stock analysts at William Blair raised their FY2024 EPS estimates for Tenax Therapeutics in a research report issued to clients and investors on Wednesday, November 13th. William Blair analyst M. Phipps now expects that the specialty pharmaceutical company will post earnings of ($0.60) per share for the year, up from their prior forecast of ($6.90). William Blair has a “Outperform” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($3.04) per share. William Blair also issued estimates for Tenax Therapeutics’ Q4 2024 earnings at ($0.14) EPS, FY2025 earnings at ($0.84) EPS, FY2026 earnings at ($0.93) EPS and FY2027 earnings at ($1.03) EPS.
Several other equities analysts have also issued reports on the company. StockNews.com initiated coverage on Tenax Therapeutics in a research note on Thursday, September 26th. They issued a “sell” rating on the stock. Leerink Partners initiated coverage on shares of Tenax Therapeutics in a research report on Thursday, October 24th. They issued an “outperform” rating and a $16.00 price objective on the stock. Leerink Partnrs raised shares of Tenax Therapeutics to a “strong-buy” rating in a research report on Thursday, October 24th. Finally, Guggenheim began coverage on shares of Tenax Therapeutics in a report on Monday, October 14th. They issued a “buy” rating and a $16.00 price target on the stock. One analyst has rated the stock with a sell rating, four have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Tenax Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $16.00.
Tenax Therapeutics Price Performance
TENX opened at $4.86 on Monday. Tenax Therapeutics has a 12 month low of $2.77 and a 12 month high of $33.44. The stock has a fifty day moving average price of $4.04 and a 200-day moving average price of $3.71.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Sphera Funds Management LTD. purchased a new stake in shares of Tenax Therapeutics during the third quarter valued at $101,000. Stonepine Capital Management LLC acquired a new stake in Tenax Therapeutics during the 3rd quarter worth about $173,000. Finally, Vestal Point Capital LP purchased a new stake in Tenax Therapeutics during the 3rd quarter valued at about $288,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.
About Tenax Therapeutics
Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Recommended Stories
- Five stocks we like better than Tenax Therapeutics
- Comparing and Trading High PE Ratio Stocks
- Super Micro Computer Soars 28%: Is It Really Out of the Woods?
- 5 Top Rated Dividend Stocks to Consider
- Traders Are Flocking Back to Oil: What’s Fueling the Optimism
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- 3 Hot Stock Trends to Ride Into 2025
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.